CINC CinCor Pharma, Inc.

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardiovascular diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension and primary aldosteronism, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

$29.14  +0.10 (0.34%)
As of 02/03/2023 15:59:59 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  01/07/2022
Outstanding shares:  43,764,323
Average volume:  1,676,097
Market cap:   $1,264,351,291
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BPCK381

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   3.47
PS ratio:   0.00
Return on equity:   -18.19%
Net income %:   0.00%